Now we have collated an inventory of suggestions from high brokerage companies from ETNow and different sources:
UBS on Bharti Airtel: Impartial | Goal value: Rs 1,595
UBS has maintained a impartial ranking on Bharti Airtel with a goal value of Rs 1,595. Q2 FY25 noticed strong ARPU development alongside manageable churn. House broadband, Africa, and Enterprise segments barely exceeded estimates, whereas Digital TV got here in barely beneath. Regardless of the general churn in subscribers, Airtel added 4.2 million 4G subscribers, indicating that disconnections have been primarily amongst low-ARPU subscribers.
Additionally Learn: Mazagon Dock among 4 stocks to trade ex-dividend tomorrow. Last chance to buy
Nomura on Macrotech Builders: Purchase | Goal value: Rs 1,600
Nomura maintained a purchase ranking on the inventory with a goal value of Rs 1,600. Q2 was robust, and H2 pre-sales are more likely to develop by 20% YoY. Pre-sales development, OCF era, and income recognition are anticipated to drive H2 development. Full-scale growth in Bangalore is now underway, focusing on a 15% market share by FY30.
Nomura on BPCL: Purchase | Goal Worth: Rs 380
Nomura has maintained a purchase name on BPCL whereas rising the goal value to Rs 380 from Rs 368. Decrease-than-anticipated outcomes have been pushed by greater LPG under-recovery, stock losses, and decrease GRM. Russian crude sourcing moderated to 34%, with PDPP now at 80% utilization. The regulatory framework on auto gas advertising margins has been supportive for OMCs.
Nuvama on Federal Financial institution: Purchase | Goal Worth: Rs 235
Nuvama maintains a purchase ranking on the inventory with a goal value of Rs 235. Q2 PAT was according to estimates, exhibiting good asset high quality. Sturdy mortgage development was noticed, however deposit development slowed down. The LCR has improved. Co-lending in MFI has simply began and stays a small portion of the portfolio. Administration stays optimistic about sustaining wholesome asset high quality in MFI.
Additionally Learn: Maruti, Adani Enterprises among 139 companies to announce Q2 results today
Jefferies on Solar Pharma: Purchase | Goal Worth: Rs 2,150
Jefferies maintained a purchase ranking on Solar Pharma and elevated the goal value to Rs 2,150 from Rs 2,000. Solar Pharma’s Q2 noticed continued development momentum within the specialty section. Q2 gross sales have been in line, whereas EBITDA and PAT have been forward of estimates attributable to decrease R&D prices. US development was pushed by greater gRevlimid gross sales and the specialty section.
R&D steerage for FY25 has been revised down attributable to slower medical trials. The corporate stays ready to launch Leqselvi following its litigation decision and is well-positioned to conclude extra offers within the specialty space.
(Disclaimer: Suggestions, strategies, views and opinions given by the specialists are their very own. These don’t symbolize the views of Financial Instances)
